[en] The main aim of this research was to demonstrate that the cortical and subcortical grey matter hypometabolism as revealed by fluorine-18 fluorodesoxyglucose-positron emission tomography ((18)F-FDG-PET) imaging in brain tumors is related to associated edema as demonstrated by magnetic resonance imaging (MRI). This in turn enhances the ability to assess disease activity in the tumor and the degree of loss of cerebral function in the adjacent and distant structures. We evaluated brain T1 and T2 weighted MRI and (18)F-FDG-PET scans of 29 patients (19 adult, 10 pediatric) with history of brain tumor. Tumor histology types included 21 gliomas, 1 melanoma, 1 primitive neuroectodermal tumor, 3 medulloblastomas and 3 ependymomas. The majority of scans were performed within the same week (94% <1 month. The extent of hypo and hypermetabolism was assessed on the (18)F-FDG-PET scans. A template of 12 regions of interest (ROI) was applied and the laterality indices of the regional counts (signal intensity) were computed. Extent of edema, enhancement, and anatomical change were assessed on the MRI scans. Extent of edema in the same ROI was evaluated by a 6-point semiquantitative scale and laterality indices were generated. Metabolic activity of the grey matter was correlated with the extent of edema using these indices. In all cases where edema was present, significant hypometabolism was observed in the adjacent structures. Overall, there was a strong correlation between the extent of edema and severity of hypometabolism (r=0.92, P=0.01). This was true regardless of the location of edema, whether there was history of radiation treatment (r=0.91, P=0.03), or not (r=0.97, P=0.17). In conclusion, edema independent of underlying variables appeared to contribute significantly to cortical and sub-cortical grey matter hypometabolism observed in patients with brain tumors. This would indicate that brain tumors can be successfully assessed by (18)F-FDG-PET and therefore the efforts for utilizing other tracers may not be justified.
Disciplines :
Neurology Radiology, nuclear medicine & imaging
Author, co-author :
Pourdehnad, Michael
Basu, Sandip
Duarte, Paulo
Okpaku, Aubrey S.
Saboury, Babak
HUSTINX, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de médecine nucléaire et imagerie onco
Alavi, Abass
Language :
English
Title :
Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET.
Dua RK, Devi BI, Yasha TC. Increased expression of Aquaporin-4 and its correlation with contrast enhancement and perilesional edema in brain tumors. Br J Neurosurg 2010; 24(4): 454-9.
Mou K, Chen M, Mao Q et al. AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha. J Neurooncol 2010; 100(3): 375-83.
Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol 1988; 6(3): 543-51. (Pubitemid 18090704)
Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995; 6(1): 19-33.
Ruderman NB, Hall TC. Use of Glucocorticoids in the Palliative Treatment of Metastatic Brain Tumors. Cancer 1965; 18: 298-306.
Reulen HJ, Huber P, Ito U, Groger U. Peritumoral brain edema. A keynote address. Adv Neurol 1990; 52: 307-15.
Hino A, Imahori Y, Tenjin H et al. Metabolic and hemodynamic aspects of peritumoral low-density areas in human brain tumor. Neurosurgery 1990; 26(4): 615-21. (Pubitemid 20120709)
Marmarou A, Takagi H, Shulman K. Biomechanics of brain edema and effects on local cerebral blood flow. Adv Neurol 1980; 28: 345-58.
Uematsu H, Maeda M, Itoh H. Peritumoral brain edema in intracranial meningiomas evaluated by dynamic perfusion-weighted MR imaging: a preliminary study. Eur Radiol 2003; 13(4): 758-62. (Pubitemid 36790558)
Behrens PF, Ostertag CB, Warnke PC. Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study. Neurosurgery 1998; 43(2): 235-40; discussion 40-1.
Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin NAm 2009; 19(4): 625-46.
Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005; 43(1): 35-47. (Pubitemid 40326558)
Spence AM, Muzi M, Mankoff DA et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004; 45(10): 1653-9.